Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

NCT05472506 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Head Cancer
Neck Cancer
Head Cancer Neck
Neck Carcinoma

Interventions

DRUG: IK-175 + nivolumab

Sponsor

Ikena Oncology

Collaborators

[object Object]